GW takes cannabinoids into diabetes and CNS indications
This article was originally published in Scrip
Following its IPO on Nasdaq in May which raised $30.4m, GW Pharmaceuticals – which develops cannabinoid-based medicines – has planned a significant amount of clinical trial activity for its pipeline in the second half of this year.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.